ACCELERON PHARMA INC. Selling, General and Administrative Expense
ACCELERON PHARMA INC. reported Selling, General and Administrative Expense of $45.11 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2021-11-04
- ACCELERON PHARMA INC. selling, general and administrative expense for the quarter ending 2021-09-30 was $45.11M, a 114.39% increase year-over-year.
- ACCELERON PHARMA INC. selling, general and administrative expense for the quarter ending 2021-06-30 was $35.47M, a 73.76% increase year-over-year.
- ACCELERON PHARMA INC. selling, general and administrative expense for the quarter ending 2021-03-31 was $31.06M, a 70.17% increase year-over-year.
- ACCELERON PHARMA INC. selling, general and administrative expense for the quarter ending 2020-12-31 was $26.21M, a 62.87% increase year-over-year.
- ACCELERON PHARMA INC. selling, general and administrative expense for fiscal 2020 was $85.91M, a 52.10% increase from fiscal 2019.
- ACCELERON PHARMA INC. selling, general and administrative expense for fiscal 2019 was $56.48M, a 63.71% increase from fiscal 2018.
- ACCELERON PHARMA INC. selling, general and administrative expense for fiscal 2018 was $34.50M, a 2.27% increase from fiscal 2017.
- ACCELERON PHARMA INC. selling, general and administrative expense for fiscal 2017 was $33.74M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2021-09-30 | $45.11M 10-Q · filed 2021-11-04 | $80.58M derived: sum of 2 quarters · filed 2021-11-04 | $111.65M 10-Q · filed 2021-11-04 | $137.85M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $35.47M 10-Q · filed 2021-08-05 | $66.53M 10-Q · filed 2021-08-05 | $92.74M derived: sum of 3 quarters · filed 2021-08-05 | $113.78M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-03-31 | $31.06M 10-Q · filed 2021-05-06 | $57.27M derived: sum of 2 quarters · filed 2021-05-06 | $78.31M derived: sum of 3 quarters · filed 2021-11-04 | $98.72M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-12-31 | $26.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $47.25M derived: sum of 2 quarters · filed 2021-11-04 | $67.66M derived: sum of 3 quarters · filed 2021-11-04 | $85.91M 10-K · filed 2021-02-25 |
| 2020-09-30 | $21.04M 10-Q · filed 2021-11-04 | $41.46M derived: sum of 2 quarters · filed 2021-11-04 | $59.70M 10-Q · filed 2021-11-04 | $75.80M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $20.41M 10-Q · filed 2021-08-05 | $38.66M 10-Q · filed 2021-08-05 | $54.76M derived: sum of 3 quarters · filed 2021-08-05 | $70.26M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $18.25M 10-Q · filed 2021-05-06 | $34.34M derived: sum of 2 quarters · filed 2021-05-06 | $49.84M derived: sum of 3 quarters · filed 2021-05-06 | $63.88M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $16.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $31.59M derived: sum of 2 quarters · filed 2021-02-25 | $45.63M derived: sum of 3 quarters · filed 2021-02-25 | $56.48M 10-K · filed 2021-02-25 |
| 2019-09-30 | $15.50M 10-Q · filed 2020-11-05 | $29.54M derived: sum of 2 quarters · filed 2020-11-05 | $40.39M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $14.04M 10-Q · filed 2020-08-06 | $24.85M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $10.81M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $34.50M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $33.74M 10-K · filed 2020-02-27 |